Photocure (PHO) - Total Liabilities
Based on the latest financial reports, Photocure (PHO) has total liabilities worth Nkr210.10 Million NOK (≈ $22.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Photocure (PHO) equity growth momentum to track the company's year-over-year net asset growth rate.
Photocure - Total Liabilities Trend (2000–2024)
This chart illustrates how Photocure's total liabilities have evolved over time, based on quarterly financial data. See Photocure free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Photocure Competitors by Total Liabilities
The table below lists competitors of Photocure ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GEVORKYAN as
PR:GEV
|
Czech Republic | Kč128.65 Million |
|
CVC Ltd
AU:CVC
|
Australia | AU$230.78 Million |
|
Fong Chien Construction Co Ltd
TWO:5523
|
Taiwan | NT$2.42 Billion |
|
Ilex Medical
TA:ILX
|
Israel | ILA286.90 Million |
|
Hsing Ta Cement Co Ltd
TW:1109
|
Taiwan | NT$1.16 Billion |
|
Ge Shen Corporation Bhd
KLSE:7197
|
Malaysia | RM192.84 Million |
|
Votum SA
WAR:VOT
|
Poland | zł279.15 Million |
|
Amber International Holding Limited
NYSE:AMBR
|
USA | $35.22 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Photocure's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PHO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.81 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Photocure's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Photocure (2000–2024)
The table below shows the annual total liabilities of Photocure from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr237.37 Million ≈ $24.98 Million |
+3.60% |
| 2023-12-31 | Nkr229.12 Million ≈ $24.11 Million |
-10.60% |
| 2022-12-31 | Nkr256.30 Million ≈ $26.97 Million |
-10.70% |
| 2021-12-31 | Nkr287.01 Million ≈ $30.20 Million |
+7.13% |
| 2020-12-31 | Nkr267.92 Million ≈ $28.19 Million |
+449.43% |
| 2019-12-31 | Nkr48.76 Million ≈ $5.13 Million |
-11.10% |
| 2018-12-31 | Nkr54.85 Million ≈ $5.77 Million |
+21.84% |
| 2017-12-31 | Nkr45.02 Million ≈ $4.74 Million |
+32.77% |
| 2016-12-31 | Nkr33.91 Million ≈ $3.57 Million |
-10.76% |
| 2015-12-31 | Nkr38.00 Million ≈ $4.00 Million |
+24.50% |
| 2014-12-31 | Nkr30.52 Million ≈ $3.21 Million |
-6.39% |
| 2013-12-31 | Nkr32.60 Million ≈ $3.43 Million |
-38.15% |
| 2012-12-31 | Nkr52.71 Million ≈ $5.55 Million |
-24.53% |
| 2011-12-31 | Nkr69.85 Million ≈ $7.35 Million |
+27.02% |
| 2010-12-31 | Nkr54.99 Million ≈ $5.79 Million |
+33.86% |
| 2009-12-31 | Nkr41.08 Million ≈ $4.32 Million |
+7.67% |
| 2008-12-31 | Nkr38.15 Million ≈ $4.01 Million |
-7.85% |
| 2007-12-31 | Nkr41.40 Million ≈ $4.36 Million |
-14.62% |
| 2006-12-31 | Nkr48.49 Million ≈ $5.10 Million |
-15.29% |
| 2005-12-31 | Nkr57.24 Million ≈ $6.02 Million |
-35.06% |
| 2004-12-31 | Nkr88.14 Million ≈ $9.28 Million |
-13.16% |
| 2003-12-31 | Nkr101.50 Million ≈ $10.68 Million |
-23.11% |
| 2002-12-31 | Nkr132.01 Million ≈ $13.89 Million |
+119.39% |
| 2001-12-31 | Nkr60.17 Million ≈ $6.33 Million |
+26.70% |
| 2000-12-31 | Nkr47.49 Million ≈ $5.00 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more